Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI0382 Formulation 2 · 1 trial · 1 indication
To evaluate bioequivalence between formulation 2 and formulation 3 of MEDI0382
To evaluate bioequivalence between formulation 2 and formulation 3 of MEDI0382.
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | formulation 2 on Day 1 and formulation 3 on Day 10 |
| Sequence 2 | EXPERIMENTAL | formulation 3 on Day 1 and formulation 2 on Day 10 |
| Name | Type | Description |
|---|---|---|
| MEDI0382 Formulation 2 | DRUG | Sequence 1 Period 1 and Sequence 2 Period 2. |
| MEDI0382 Formulation 3 | DRUG | Sequence 1 Period 2 and Sequence 2 Period 1 |
Inclusion Criteria: 1. Healthy subjects age 18 through 45 years at the time of screening. 2. Provision of signed and dated written informed consent prior to study-specific procedures. 3. Body mass index between 19 and 30 kg/m2 (inclusive) at screening 4. Good general health as judged by the investi...
MEDI0382 Formulation 2 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 1 clinical development, with one completed trial in the United States. The drug is not yet approved and remains under investigation.
MEDI0382 Formulation 2 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting clinical trials to evaluate this investigational drug for Type 2 Diabetes Mellitus.
MEDI0382 Formulation 2 is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 24 participants in the United States. The drug is investigational and has not received regulatory approval for any use.
MEDI0382 Formulation 2 has one completed clinical trial, identified as NCT03341013. This Phase 1 study investigated bioequivalence between a single dose of Formulation 2 and Formulation 3 of MEDI0382 in healthy volunteers with Type 2 Diabetes Mellitus.
MEDI0382 Formulation 2 is a specific formulation of the drug MEDI0382. The clinical trial NCT03341013 compared this formulation with Formulation 3 of the same drug. Both formulations are being evaluated for the treatment of Type 2 Diabetes Mellitus.